What You Should Know:
– CustoMED, a pioneer in AI-driven, surgeon-first platforms for patient-specific orthopedic solutions, announced the successful completion of its seed round, bringing total funding to $6M.
– The investment round includes participation from Longevity Venture Partners, Varana Capital, Flag Capital, the Israel Innovation Authority, a leading orthopedic implant company, and Avishai Abrahami, Co-founder and CEO of Wix.
Accelerating Personalized Surgery from Weeks to Minutes
CustoMED’s cloud-based platform is transforming orthopedic surgery by eliminating the lengthy delays traditionally associated with personalized device creation. The platform combines artificial intelligence (AI) and automation with 3D printing to generate surgical tools and implants directly from a surgeon’s pre-operative plan within minutes instead of weeks.
This technology enables:
- Fewer Intraoperative Errors: Providing perfect adherence to the surgical plan.
- Predictable Outcomes: Allowing surgeons to maintain full clinical control with enhanced precision.
- Scalable Delivery: Patient-specific devices are produced onsite or through certified partners and integrate seamlessly into existing surgical workflows.
“CustoMED’s patient-specific surgical tools enable more precise orthopedic surgeries through affordable, real-time solutions delivered directly into the operating room,” said Or Benifla, Co-founder of CustoMED. The mission is to transform what was once a boutique process into the standard of care for every patient.
Origin in Clinical Innovation and Global Deployment
CustoMED was founded by Dr. Amit Zabatani, Or Benifla, and Alon Jacobi, and originated from Sheba Medical Center’s 3D Printing & Innovation Lab. The lab has already made 3D technologies a routine part of patient care, supporting hundreds of surgeries across multiple hospital departments.
The company is part of Sheba Medical Center’s ARC Innovation ecosystem, which accelerates global deployment by fostering clinician-led innovations. Prof. Eyal Zimlichman, Founder and Director of ARC Innovation, stated that CustoMED “is embedding precision and surgeon-directed tools into everyday workflows, shortening the path from imaging to the operating room while preserving governance, quality, and safety.”.
Expansion Plans
The proceeds from the funding round will be used to accelerate CustoMED’s expansion into additional automated orthopedic indications and support U.S. and EU regulatory milestones, with approvals anticipated for 2026. The capital will also enable the global deployment of its on-demand manufacturing model.
